Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 6/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | RARG | P13631 | 1/20 | 0.40 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | AHR | P35869 | 1/20 | 0.37 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 4/20 | 0.34 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29706774 | 1.00 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL2242248 | 0.82 | BCHE (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL8700087 | 0.79 | BCHE (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL6797508 | 0.78 | RARB (0.39) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL23675002 | 0.77 | RARB (0.40) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL31714583 | 0.77 | RARB (0.40) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL3797862 | 0.76 | HDAC3 (0.41) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL29706809 | 0.76 | MAP3K5 (0.44) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL16896885 | 0.75 | GRIN2D (0.41) | HDAC3HDAC4HDAC1HDAC2HDAC8 | |
| SCHEMBL26443454 | 0.75 | RARB (0.39) | HDAC3HDAC4HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3145915-B1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-114585616-B | Amide derivatives and their use in medicine | 广东东阳光药业股份有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-114585616-A | Amide derivatives and their use in medicine | 广东东阳光药业有限公司 | 2022-06-03 | — | — | CN | disclosed |
| WO-2021031071-A1 | AMIDE DERIVATIVE AND USE THEREOF IN MEDICINE | 广东东阳光药业有限公司 | 2021-02-25 | — | — | WO | disclosed |
| US-10000454-B2 | Antidiabetic tricyclic compounds | MERCK SHARP & DOHME (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2017-03-23 | — | — | US | disclosed |
| WO-2015176267-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000454-B2 | Antidiabetic tricyclic compounds | GPR119, GPR65, GPR52 | HDAC3 391/4885HDAC4 549/4885HDAC1 584/4885 |
| US-20170081287-A1 | ANTIDIABETIC TRICYCLIC COMPOUNDS | GPR119, GPR65, GPR52 | HDAC3 391/4885HDAC4 549/4885HDAC1 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.